Compugen Appoints Mr. Avihai Shen Interim CFO
May 12 2014 - 7:00AM
Business Wire
Compugen Ltd. (NASDAQ: CGEN) today announced the appointment of
Mr. Avihai Shen as Interim Chief Financial Officer, replacing Ms.
Dikla Czaczkes Axselbrad.
Dr. Anat Cohen-Dayag, Compugen’s President and CEO, stated, “The
Company and Dikla agreed that Dikla would step down from her
position as the Company’s CFO. We thank her for her contributions
and wish her every success in her future endeavors.”
Mr. Shen recently replaced Ms. Czaczkes Axselbrad at Compugen
while she was on maternity leave and therefore is fully capable of
stepping in immediately as the Company’s interim CFO. Mr. Shen has
extensive experience as a chief financial officer for both public
and private companies. Prior to his activities at Compugen, Mr.
Shen has served as CFO at Delek Energy US, Retalix US and Arotech
Corp. He began his career as a certified public accountant with
Ernst and Young.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of product
candidates, which are then advanced in its Pipeline Program. The
Company's business model includes collaborations covering the
further development and commercialization of product candidates at
various stages from its Pipeline Program and various forms of
research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. Compugen’s wholly-owned U.S.
subsidiary located in South San Francisco is developing oncology
and immunology monoclonal antibody therapeutic candidates against
its drug targets. For additional information, please visit
Compugen's corporate website at http://www.cgen.com/.
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include words such as “may,” “expects,”
“anticipates,” “potential,” “believes,” and “intends,” and describe
opinions about future events. These forward-looking statements
involve known and unknown risks and uncertainties that may cause
the actual results, performance or achievements of Compugen to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking
statements. Some of these risks and other factors are discussed in
the "Risk Factors" section of Compugen’s Annual Report on Form 20-F
for the year ended December 31, 2013 as filed with the Securities
and Exchange Commission. In addition, any forward-looking
statements represent Compugen’s views only as of the date of this
release and should not be relied upon as representing its views as
of any subsequent date. Compugen does not assume any obligation to
update any forward-looking statements unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024